These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25318123)

  • 1. Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections.
    Chang J; Block TM; Guo JT
    Antivir Ther; 2015; 20(3):257-9. PubMed ID: 25318123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycosylation, hypogammaglobulinemia, and resistance to viral infections.
    Sadat MA; Moir S; Chun TW; Lusso P; Kaplan G; Wolfe L; Memoli MJ; He M; Vega H; Kim LJY; Huang Y; Hussein N; Nievas E; Mitchell R; Garofalo M; Louie A; Ireland DC; Grunes C; Cimbro R; Patel V; Holzapfel G; Salahuddin D; Bristol T; Adams D; Marciano BE; Hegde M; Li Y; Calvo KR; Stoddard J; Justement JS; Jacques J; Priel DAL; Murray D; Sun P; Kuhns DB; Boerkoel CF; Chiorini JA; Di Pasquale G; Verthelyi D; Rosenzweig SD
    N Engl J Med; 2014 Apr; 370(17):1615-1625. PubMed ID: 24716661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abrogation of glucosidase I-mediated glycoprotein deglucosylation results in a sick phenotype in fission yeasts: Model for the human MOGS-CDG disorder.
    Gallo GL; Valko A; Aramburu SI; Etchegaray E; Völker C; Parodi AJ; D'Alessio C
    J Biol Chem; 2018 Dec; 293(52):19957-19973. PubMed ID: 30389790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mannosyl-oligosaccharide glucosidase - congenital disorder of glycosylation: A patient with novel variants.
    Ota M; Miyahara J; Itano A; Sugiura H; Ohki S
    Pediatr Int; 2020 Mar; 62(3):417-418. PubMed ID: 32246563
    [No Abstract]   [Full Text] [Related]  

  • 5. Compound heterozygous variants in MOGS inducing congenital disorders of glycosylation (CDG) IIb.
    Li M; Xu Y; Wang Y; Yang XA; Jin D
    J Hum Genet; 2019 Mar; 64(3):265-268. PubMed ID: 30587846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congenital disorders of glycosylation type IIb with MOGS mutations cause early infantile epileptic encephalopathy, dysmorphic features, and hepatic dysfunction.
    Anzai R; Tsuji M; Yamashita S; Wada Y; Okamoto N; Saitsu H; Matsumoto N; Goto T
    Brain Dev; 2021 Mar; 43(3):402-410. PubMed ID: 33261925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of novel mutations in MOGS in a Chinese patient with infantile spams.
    Peiwei Zhao ; Peng X; Luo S; Huang Y; Tan L; Shao J; He X
    Neurogenetics; 2020 Apr; 21(2):97-104. PubMed ID: 31925597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions.
    Chang J; Block TM; Guo JT
    Antiviral Res; 2013 Sep; 99(3):251-60. PubMed ID: 23816430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Insights into the Broad-Spectrum Antiviral Target Endoplasmic Reticulum Alpha-Glucosidase II.
    Caputo AT; Alonzi DS; Kiappes JL; Struwe WB; Cross A; Basu S; Darlot B; Roversi P; Zitzmann N
    Adv Exp Med Biol; 2018; 1062():265-276. PubMed ID: 29845539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristic dysmorphic features in congenital disorders of glycosylation type IIb.
    Kim YM; Seo GH; Jung E; Jang JH; Kim SZ; Lee BH
    J Hum Genet; 2018 Mar; 63(3):383-386. PubMed ID: 29235540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitotic Intragenic Recombination: A Mechanism of Survival for Several Congenital Disorders of Glycosylation.
    Kane MS; Davids M; Adams C; Wolfe LA; Cheung HW; Gropman A; Huang Y; ; Ng BG; Freeze HH; Adams DR; Gahl WA; Boerkoel CF
    Am J Hum Genet; 2016 Feb; 98(2):339-46. PubMed ID: 26805780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum N-glycomics of a novel CDG-IIb patient reveals aberrant IgG glycosylation.
    Beimdiek J; Hennig R; Burock R; Puk O; Biskup S; Rapp E; Lesinski-Schiedat A; Buettner FFR; Das AM
    Glycobiology; 2022 Apr; 32(5):380-390. PubMed ID: 35137040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.
    Ma J; Zhang X; Soloveva V; Warren T; Guo F; Wu S; Lu H; Guo J; Su Q; Shen H; Solon E; Comunale MA; Mehta A; Guo JT; Bavari S; Du Y; Block TM; Chang J
    Antiviral Res; 2018 Feb; 150():112-122. PubMed ID: 29253498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficiency of α-glucosidase I alters glycoprotein glycosylation and lifespan in Caenorhabditis elegans.
    Katoh T; Takase J; Tani Y; Amamoto R; Aoshima N; Tiemeyer M; Yamamoto K; Ashida H
    Glycobiology; 2013 Oct; 23(10):1142-51. PubMed ID: 23836288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Antiviral Activity of Iminosugars Against Dengue Virus.
    Miller JL; Tyrrell BE; Zitzmann N
    Adv Exp Med Biol; 2018; 1062():277-301. PubMed ID: 29845540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, biochemical and genetic characteristics of MOGS-CDG: a rare congenital disorder of glycosylation.
    Shimada S; Ng BG; White AL; Nickander KK; Turgeon C; Liedtke KL; Lam CT; Font-Montgomery E; Lourenco CM; He M; Peck DS; Umana LA; Uhles CL; Haynes D; Wheeler PG; Bamshad MJ; Nickerson DA; Cushing T; Gates R; Gomez-Ospina N; Byers HM; ; Scalco FB; Martinez NN; Sachdev R; Smith L; Poduri A; Malone S; Harris RV; Scheffer IE; Rosenzweig SD; Adams DR; Gahl WA; Malicdan MCV; Raymond KM; Freeze HH; Wolfe LA
    J Med Genet; 2022 Jul; ():. PubMed ID: 35790351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated clinical and glycomic features of mannosyl-oligosaccharide glucosidase deficiency: Two case reports.
    Abuduxikuer K; Wang L; Zou L; Cao CY; Yu L; Guo HM; Liang XM; Wang JS; Chen L
    World J Clin Cases; 2022 Jul; 10(21):7397-7408. PubMed ID: 36158009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epilepsy and movement disorders in CDG: Report on the oldest-known MOGS-CDG patient.
    Lo Barco T; Osanni E; Bordugo A; Rodella G; Iascone M; Tenconi R; Barone R; Dalla Bernardina B; Cantalupo G
    Am J Med Genet A; 2021 Jan; 185(1):219-222. PubMed ID: 33058492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Processing of N-linked carbohydrate chains in a patient with glucosidase I deficiency (CDG type IIb).
    Völker C; De Praeter CM; Hardt B; Breuer W; Kalz-Füller B; Van Coster RN; Bause E
    Glycobiology; 2002 Aug; 12(8):473-83. PubMed ID: 12145188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Endoplasmic Reticulum α-Glucosidase I with a Single-Dose Iminosugar Treatment Protects against Lethal Influenza and Dengue Virus Infections.
    Warfield KL; Alonzi DS; Hill JC; Caputo AT; Roversi P; Kiappes JL; Sheets N; Duchars M; Dwek RA; Biggins J; Barnard D; Shresta S; Treston AM; Zitzmann N
    J Med Chem; 2020 Apr; 63(8):4205-4214. PubMed ID: 32227946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.